secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001193125-24-028396
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Samuel Broder resigns from Sensei Biotherapeutics board; board reduced to eight
--------------------------------------------------------------------------------

- Samuel Broder, MD resigned from the Board effective February 5, 2024, not due to any disagreement with the Company.
- Dr. Broder will remain as a consultant providing strategic guidance on science, clinical development, and regulatory pathways.
- Board reduced from nine to eight directors effective February 6, 2024.
- Bill Ringo appointed as Interim Chair of the Nominating and Corporate Governance Committee, effective immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524028396/0001193125-24-028396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524028396/d778564d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-028396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer